Sterling Capital Management’s Monopar Therapeutics MNPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.29K Buy
104
+32
+44% +$3.43K ﹤0.01% 2614
2026
Q2
$6.67K Buy
72
+43
+148% +$2.66K ﹤0.01% 2457
2026
Q1
$1.59K Hold
29
– – ﹤0.01% 3032
2025
Q4
$1.89K Buy
29
+20
+222% +$1.63K ﹤0.01% 3074
2025
Q3
$735 Sell
9
-1
-10% -$45 ﹤0.01% 3122
2025
Q2
$358 Buy
+10
New +$363 ﹤0.01% 3191

Other funds holding MNPR

Sterling Capital Management's MNPR Position: Q3 2026 in Review

Sterling Capital Management increased its Monopar Therapeutics (MNPR) stake by 44% in Q3 2026, buying an estimated $3.43K and bringing the position to 104 shares worth $8.29K. The position accounts for ﹤0.01% of the portfolio, ranked #2614.

Sterling Capital Management first reported a position in MNPR in Q2 2025 and has held it in 6 quarters since. 106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

  • Sterling Capital Management held 104 shares of Monopar Therapeutics worth $8.29K as of Q3 2026.
  • Sterling Capital Management bought 32 Monopar Therapeutics shares in Q3 2026, an estimated $3.43K.
  • Monopar Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2614 holding.
  • Sterling Capital Management first reported a position in Monopar Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.